Asset
Tirzepatide
Eli Lilly and Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $14.9B |
| Q1 2026 | $12.8B |
| Q4 2025 | $11.7B |
| Q3 2025 | $10.1B |
| Q2 2025 | $8.6B |
| Q1 2025 | $6.2B |
| Q4 2024 | $5.4B |
| Q3 2024 | $4.4B |
| Q2 2024 | $4.3B |
| Q1 2024 | $2.3B |
| Q3 2023 | $1.4B |
| Q2 2023 | $979.7M |
| Q1 2023 | $568.5M |
| Q4 2022 | $279.3M |
| Q3 2022 | $187.3M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (74)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06962280 | phase3 | active_not_recruiting | 2025-05-12 | 2026-11-01 | Eli Lilly and Company | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight |
| NCT03861039 | phase3 | completed | 2019-03-30 | 2021-01-26 | Eli Lilly and Company | A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes |
| NCT06143956 | phase2 | recruiting | 2023-11-17 | 2027-09-01 | Eli Lilly and Company | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight |
| NCT07165028 | phase3 | recruiting | 2025-10-15 | 2030-08-01 | Eli Lilly and Company | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) |
| NCT05810597 | phase1 | completed | 2023-04-03 | 2023-07-17 | Eli Lilly and Company | A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices |
FDA applications (2)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| NDA 217806 | 2023-11-08 | NDA | ELI LILLY AND CO |
| NDA 215866 | 2022-05-13 | NDA | ELI LILLY AND CO |
Marketed products (48)
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO
- MOUNJARO (AUTOINJECTOR)
- MOUNJARO (AUTOINJECTOR)
- MOUNJARO (AUTOINJECTOR)
- MOUNJARO (AUTOINJECTOR)
- MOUNJARO (AUTOINJECTOR)
- MOUNJARO (AUTOINJECTOR)
- MOUNJARO KWIKPEN
- MOUNJARO KWIKPEN
- MOUNJARO KWIKPEN
- MOUNJARO KWIKPEN
- MOUNJARO KWIKPEN
- MOUNJARO KWIKPEN
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND
- ZEPBOUND (AUTOINJECTOR)
- ZEPBOUND (AUTOINJECTOR)
- ZEPBOUND (AUTOINJECTOR)
- ZEPBOUND (AUTOINJECTOR)
- ZEPBOUND (AUTOINJECTOR)
- ZEPBOUND (AUTOINJECTOR)
- ZEPBOUND KWIKPEN
- ZEPBOUND KWIKPEN
- ZEPBOUND KWIKPEN
- ZEPBOUND KWIKPEN
- ZEPBOUND KWIKPEN
- ZEPBOUND KWIKPEN